PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS-MedSci.cn

PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS

Bledsoe, AC; Hazan, S; Genta, RM; Falk, GW; Boren, K; Peterson, KA; Pasha, M; Singh, B; Chang, AT; Kamboj, AP; Rasmussen, HS; Hirano, I; Dellon, ES

GASTROENTEROLOGY, 2020; 158 (6): S52

科室
- - 订阅+
  - 更多科室
工具
服务